Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17500
Corporate User License Price USD 750
Corporate User License Price INR 52500
Site License Price USD 500
Site License Price INR 35000
Request a Quote

Report Title

MallInckrodt Plc (MNK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

MallInckrodt Plc (MNK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

MallInckrodt Plc (MNK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

MallInckrodt Plc (MNK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

Mallinckrodt Plc (Mallinckrodt) is develops, produces, commercializes, and distributes specialty pharmaceutical therapies and products. The company offers both branded and specialty generics for autoimmune and rare diseases in the specialty therapeutic areas of rheumatology, nephrology, neurology, pulmonology and ophthalmology. It also offers analgesics and gastrointestinal products and immunotherapy and neonatal respiratory critical care therapies; active pharmaceutical ingredients (APIs) and external manufacturing services. The company sells its products either directly or through distributors to retail pharmacies, institutions and various end users. It has subsidiaries in Prince Edward Island, Ireland, Bermuda, Germany, Australia, Canada, Maryland, Delaware, Massachusetts, the UK, California, Netherlands, Alberta, Switzerland, and Luxembourg. Mallinckrodt is headquartered in Surrey, the UK.

MallInckrodt Plc (MNK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

MallInckrodt Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

MallInckrodt Plc, Medical Devices Deals, 2012 to YTD 2018 13

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deal Details 18

Asset Purchase 18

Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company 18

Biovectra to Acquire Manufacturing Facility from Sepracor Canada 20

Questcor Pharma Acquires Rights To Synacthen And Synacthen Depot 21

Mallinckrodt Completes Acquisition Of Rights To Roxicodone From Xanodyne Pharma 23

Venture Financing 24

InfaCare Pharma Raises USD3.5 Million in Venture Financing 24

Infacare Pharma Raises USD5.5 Million in Venture Financing 25

Vtesse Raises USD17 Million in Extended Series A Financing 26

Vtesse Raises USD25 Million in Series A Financing 27

Infacare Pharma Raises USD1.3 Million in Venture Financing 28

Athyrium Opportunities Invests in Ikaria 29

Ocera Therapeutics Raises USD 20 Million In Venture Financing 30

Infacare Pharma Raises USD 3.6 Million In First Tranche Of Series C Financing 31

Ocera Therapeutics Raises USD 1.5 Million In Venture Financing 33

Partnerships 35

Questcor Pharma Enters Into Licensing Agreement With European Company To Develop Novel Melanocortin Peptides 35

Mallinckrodt Enters into Research Partnership with Washington University 36

Mesoblast Enters into Agreement with Mallinckrodt Pharma 37

Valeo Pharma Enters into Distribution Agreement with Questcor Pharma for Synacthen Depot 38

Vtesse Enters into Agreement with National Institutes of Health for VTS-270 39

INO Therapeutics Enters into Agreement with Lee's Pharma for Inomax 40

Mallinckrodt Pharma And Medtronic Enter Into Clinical Agreement For Intrathecal Therapeutics 41

Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 42

Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 43

Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 44

BioVectra Enters Into Co-Marketing Agreement With Quanta BioSciences 45

Merger 46

Ocera Therapeutics And Tranzyme Pharma Complete Merger 46

Licensing Agreements 48

Sucampo Exercises Option for Licensing Agreement with Cancer Prevention Pharma 48

Sucampo Enters into Licensing Agreement with Cancer Prevention Pharma 49

BioVectra Enters into Licensing Agreement with TUBE Pharmaceuticals 50

West Pharma Enters into Licensing Agreement with Mallinckrodt 51

Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 52

Sucampo Pharma Enters into Option Agreement with Cancer Prevention Pharma 53

Sucampo Pharma Enters into Licensing Agreement with Harbin Gloria Pharma 54

Vtesse Enters into Licensing Agreement with National Institutes of Health for Cyclodextrins 55

Sucampo Pharma Enters Into Licensing Agreement with Takeda Pharma 56

Lyric Pharma Enters into Licensing Agreement with Ocera Therapeutics 58

Ocera Therapeutics Enters Into Technology Transfer and License Agreement With F. Hoffmann-La Roche 59

Sucampo Pharma and R-Tech Ueno Enter into Licensing Agreement with Par Pharma 60

Equity Offering 61

Sucampo Pharma Plans to Raise Funds through Public Offering of shares 61

Ocera Therapeutics Raises Funds through Private Placement of Shares 62

Ocera Therapeutics Raises USD25.5 Million in Public Offering of Shares 63

Vtesse Spin Out from Cydan Development 64

Ocera Therapeutics Raises USD25.2 Million in Public Offering of Shares 65

Ocera Therapeutics Completes Private Placement Of Units For USD 28 Million 67

Sucampo Pharma Files Registration Statement For Public Offering Of Securities For USD 150 Million 69

Debt Offering 70

Sucampo Pharma Raises USD300 Million in Private Placement of 3.25% Notes Due 2021 70

Mallinckrodt to Raise USD750 Million in Private Placement of Notes Due 2023 71

Mallinckrodt to Raise up to USD1.2 Billion in Private Placement of Notes 72

Asset Transactions 73

Baxter International Acquires Two Hemostat and Sealant Products from Mallinckrodt 73

Aurobindo Pharma Denies Acquisition of Generic Drug Unit from Mallinckrodt 74

Piramal Enterprises Acquires Intrathecal Therapy Business from Mallinckrodt for 203 Million 75

Numab Acquires ND003 From Sucampo 77

Acquisition 78

Mallinckrodt Acquires Sucampo Pharma for USD1.2 Billion 78

Mallinckrodt Acquires Ocera Therapeutics for up to USD117 Million 80

Mallinckrodt Acquires InfaCare Pharma 82

Sucampo Pharma Acquires Vtesse for USD200 Million 83

Mallinckrodt Acquires Stratatech 84

Sucampo Pharma Acquires R-Tech Ueno for USD274.5 Million in Tender Offer 85

Mallinckrodt Pharma Acquires Therakos from Gores Group 87

Mallinckrodt Acquires Ikaria for up to USD2.3 Billion 89

Mallinckrodt Acquires Questcor Pharma for USD5.6 Billion 91

Mallinckrodt Completes Acquisition Of Cadence Pharma For USD 1.4 Billion In Tender Offer 93

Questcor Pharma Completes Acquisition Of BioVectra, Contract Manufacturing Company, For USD 101 Million 95

Mallinckrodt Completes Acquisition Of CNS Therapeutics For USD 100 Million 96

MallInckrodt Plc-Key Competitors 98

MallInckrodt Plc-Key Employees 99

MallInckrodt Plc-Locations And Subsidiaries 100

Head Office 100

Other Locations & Subsidiaries 100

Recent Developments 104

Strategy And Business Planning 104

Oct 16, 2017: Mallinckrodt Opens Specialty Brands Office In New Jersey, Announces USD 100,000 Donation To Princeton University Program For High Achieving, Low-Income High School Students 104

May 15, 2017: Mallinckrodt Opens New Global Centre for Medical Device R&D 105

Financial Announcements 106

Aug 07, 2018: Mallinckrodt reports second quarter 2018 results and raises guidance for 2018 106

May 08, 2018: Mallinckrodt Reports First Quarter 2018 Results 108

Feb 27, 2018: Mallinckrodt Reports Fourth Quarter and Fiscal 2017 Results, Announces 2018 Guidance and Sets 2018 Strategic Priorities 110

Nov 07, 2017: Mallinckrodt Reports Earnings Results for Third Quarter of Fiscal 2017 112

Aug 08, 2017: Mallinckrodt Reports Earnings Results for Second Quarter of Fiscal 2017 114

May 08, 2017: Mallinckrodt Reports Earnings Results for First Quarter of Fiscal 2017 116

Feb 07, 2017: Mallinckrodt Reports Transition Period Results and Announces 2017 Guidance 118

Corporate Communications 120

Oct 01, 2018: Mallinckrodt responds to CBS' 60 minutes segment 120

Jun 21, 2018: Mallinckrodt Launches Scientific Advisory Council 121

Apr 04, 2018: Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of the Board in May 2018 122

Apr 04, 2018: Mallinckrodt Names Paul R. Carter, Anne C. Whitaker to its Board of Directors 123

Sep 20, 2017: Mallinckrodt Announces Election Of David Norton To Its Board Of Directors 124

May 19, 2017: Mallinckrodt Donates GBP100,000 to Ashford and St. Peter's Hospitals NHS Foundation Trust to Support Neonatal Care 125

Jan 04, 2017: Karen Sheehy to Succeed Raymond Furey as Chief Compliance Officer of Mallinckrodt 126

Legal and Regulatory 127

Sep 22, 2017: Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse in the United States 127

Aug 04, 2017: Mallinckrodt Statement On Lawsuit Filed By Multnomah County, Oregon, Related To Opioid Products 128

Aug 02, 2017: Mallinckrodt Statement on U.S. DOJ Subpoena Related to Opioid Products 129

Government and Public Interest 130

Aug 06, 2018: Mallinckrodt boosts rare-disease research at Washington University 130

Product News 131

08/10/2017: Study Results Published in The Lancet Demonstrate Safety and Efficacy of Intrathecal VTS-270 in Niemann-Pick Disease Type C1 131

07/17/2017: NIH scientists find rare disease clues in cell's recycling system 132

06/01/2017: Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis 133

05/26/2017: Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease 134

04/18/2017: New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Disease Type C1 135

03/15/2017: Vtesse Completes Enrollment of Phase 2b/3 Pivotal Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease 136

Clinical Trials 137

Feb 14, 2018: Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft C9T1 Skin Tissue 137

Oct 20, 2017: Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting 138

Sep 28, 2017: Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation 140

Aug 23, 2017: Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting 2017 141

Apr 12, 2017: Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease 142

Mar 08, 2017: Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy 143

Jan 30, 2017: Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy 144

Jan 05, 2017: Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis 145

Other Significant Developments 146

Aug 09, 2018: New Mallinckrodt data analysis shows limited use of opioid-free analgesia, underutilization in some patients more prone to opioid-related adverse events 146

Aug 01, 2018: Mallinckrodt initiates proof-of-concept study of nitric oxide gas in ex-vivo system of human lung transplants 147

Sep 12, 2017: Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other Matters 148

Aug 30, 2017: Mallinckrodt Statement on Missouri Attorney General Investigation 150

Jul 27, 2017: Mallinckrodt Will Respond to Sen. McCaskill's Request for Information on Opioid Anti-Diversion and Suspicious Order Monitoring Activities 151

Jun 21, 2017: Mallinckrodt and Massachusetts Health & Hospital Association Announce Joint Initiative for Developing Pain Stewardship Programs Within Hospitals 152

Jun 06, 2017: Mallinckrodt Updates Facts Refuting Short-Seller Claims 153

Apr 03, 2017: Mallinckrodt Statement on DEA and USAOs Agreement in Principle 155

Jan 18, 2017: Mallinckrodt Responds to Media Reports Regarding Previously Disclosed FTC Investigation 156

Appendix 157

Methodology 157

About GlobalData 157

Contact Us 157

Disclaimer 157

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

MallInckrodt Plc, Medical Devices Deals, 2012 to YTD 2018 13

List of Tables

MallInckrodt Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

MallInckrodt Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

MallInckrodt Plc, Deals By Therapy Area, 2012 to YTD 2018 11

MallInckrodt Plc, Medical Devices Deals, 2012 to YTD 2018 13

MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company 18

Biovectra to Acquire Manufacturing Facility from Sepracor Canada 20

Questcor Pharma Acquires Rights To Synacthen And Synacthen Depot 21

Mallinckrodt Completes Acquisition Of Rights To Roxicodone From Xanodyne Pharma 23

InfaCare Pharma Raises USD3.5 Million in Venture Financing 24

Infacare Pharma Raises USD5.5 Million in Venture Financing 25

Vtesse Raises USD17 Million in Extended Series A Financing 26

Vtesse Raises USD25 Million in Series A Financing 27

Infacare Pharma Raises USD1.3 Million in Venture Financing 28

Athyrium Opportunities Invests in Ikaria 29

Ocera Therapeutics Raises USD 20 Million In Venture Financing 30

Infacare Pharma Raises USD 3.6 Million In First Tranche Of Series C Financing 31

Ocera Therapeutics Raises USD 1.5 Million In Venture Financing 33

Questcor Pharma Enters Into Licensing Agreement With European Company To Develop Novel Melanocortin Peptides 35

Mallinckrodt Enters into Research Partnership with Washington University 36

Mesoblast Enters into Agreement with Mallinckrodt Pharma 37

Valeo Pharma Enters into Distribution Agreement with Questcor Pharma for Synacthen Depot 38

Vtesse Enters into Agreement with National Institutes of Health for VTS-270 39

INO Therapeutics Enters into Agreement with Lee's Pharma for Inomax 40

Mallinckrodt Pharma And Medtronic Enter Into Clinical Agreement For Intrathecal Therapeutics 41

Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 42

Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 43

Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 44

BioVectra Enters Into Co-Marketing Agreement With Quanta BioSciences 45

Ocera Therapeutics And Tranzyme Pharma Complete Merger 46

Sucampo Exercises Option for Licensing Agreement with Cancer Prevention Pharma 48

Sucampo Enters into Licensing Agreement with Cancer Prevention Pharma 49

BioVectra Enters into Licensing Agreement with TUBE Pharmaceuticals 50

West Pharma Enters into Licensing Agreement with Mallinckrodt 51

Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 52

Sucampo Pharma Enters into Option Agreement with Cancer Prevention Pharma 53

Sucampo Pharma Enters into Licensing Agreement with Harbin Gloria Pharma 54

Vtesse Enters into Licensing Agreement with National Institutes of Health for Cyclodextrins 55

Sucampo Pharma Enters Into Licensing Agreement with Takeda Pharma 56

Lyric Pharma Enters into Licensing Agreement with Ocera Therapeutics 58

Ocera Therapeutics Enters Into Technology Transfer and License Agreement With F. Hoffmann-La Roche 59

Sucampo Pharma and R-Tech Ueno Enter into Licensing Agreement with Par Pharma 60

Sucampo Pharma Plans to Raise Funds through Public Offering of shares 61

Ocera Therapeutics Raises Funds through Private Placement of Shares 62

Ocera Therapeutics Raises USD25.5 Million in Public Offering of Shares 63

Vtesse Spin Out from Cydan Development 64

Ocera Therapeutics Raises USD25.2 Million in Public Offering of Shares 65

Ocera Therapeutics Completes Private Placement Of Units For USD 28 Million 67

Sucampo Pharma Files Registration Statement For Public Offering Of Securities For USD 150 Million 69

Sucampo Pharma Raises USD300 Million in Private Placement of 3.25% Notes Due 2021 70

Mallinckrodt to Raise USD750 Million in Private Placement of Notes Due 2023 71

Mallinckrodt to Raise up to USD1.2 Billion in Private Placement of Notes 72

Baxter International Acquires Two Hemostat and Sealant Products from Mallinckrodt 73

Aurobindo Pharma Denies Acquisition of Generic Drug Unit from Mallinckrodt 74

Piramal Enterprises Acquires Intrathecal Therapy Business from Mallinckrodt for 203 Million 75

Numab Acquires ND003 From Sucampo 77

Mallinckrodt Acquires Sucampo Pharma for USD1.2 Billion 78

Mallinckrodt Acquires Ocera Therapeutics for up to USD117 Million 80

Mallinckrodt Acquires InfaCare Pharma 82

Sucampo Pharma Acquires Vtesse for USD200 Million 83

Mallinckrodt Acquires Stratatech 84

Sucampo Pharma Acquires R-Tech Ueno for USD274.5 Million in Tender Offer 85

Mallinckrodt Pharma Acquires Therakos from Gores Group 87

Mallinckrodt Acquires Ikaria for up to USD2.3 Billion 89

Mallinckrodt Acquires Questcor Pharma for USD5.6 Billion 91

Mallinckrodt Completes Acquisition Of Cadence Pharma For USD 1.4 Billion In Tender Offer 93

Questcor Pharma Completes Acquisition Of BioVectra, Contract Manufacturing Company, For USD 101 Million 95

Mallinckrodt Completes Acquisition Of CNS Therapeutics For USD 100 Million 96

MallInckrodt Plc, Key Competitors 98

MallInckrodt Plc, Key Employees 99

MallInckrodt Plc, Other Locations 100

MallInckrodt Plc, Subsidiaries 100

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

MallInckrodt Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person